← All trials
NCT06697522
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2023
- Primary completion
- Oct 6, 2023
- Completion date
- Mar 26, 2024
- First posted
- Nov 20, 2024
- Last posted
- Nov 20, 2024
- Enrollment
- 148
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ocumension Therapeutics (Shanghai) Co., LtdLead sponsor
- Capital Medical UniversityOfficial
- Capital Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.